rss
Br J Ophthalmol 2008;92:231-235 doi:10.1136/bjo.2007.130062
  • Original Article

Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood–brain barrier disruption

  1. J Vicuna-Kojchen1,
  2. S Frenkel1,
  3. T Siegal2,
  4. E Shalom2,
  5. I Chowers1,
  6. J Pe’er1
  1. 1
    Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  2. 2
    Gaffin Center for Neuro-Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  1. Professor Jacob Pe’er, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, POB 12000, Jerusalem 91120, Israel; peer{at}hadassah.org.il
  • Accepted 5 November 2007

Abstract

Aim: To determine the incidence and characteristics of maculopathy associated with blood–brain barrier disruption (BBBD) which is used in treating primary central nervous system lymphoma (PCNSL).

Methods: Files of all 56 patients with PCNSL, with or without intraocular lymphoma (IOL), treated at Hadassah University Hospital during the years 1997–2007 were reviewed. Data on 46 patients for whom we had documentation of ocular examination were studied. Those who were alive at the time of the data collection were invited for further evaluation of the presence or absence of maculopathy. The patients were divided into four groups according to treatment protocol. Group 1: systemic intravenous chemotherapy; Group 2: systemic intravenous chemotherapy and intravitreal methotrexate (MTX); Group 3: systemic intra-arterial (IA) chemotherapy and BBBD; Group 4: systemic IA chemotherapy, BBBD, and intravitreal MTX.

Results: Of the 23 patients of Groups 1 and 2 who were not treated by BBBD, none developed maculopathy. Of those 23 patients who were treated by BBBD, 12 of 17 (70.5%) in Group 3 and three of six (50%) in Group 4, for a total of 15 of 23 (65.2%) developed maculopathy. The maculopathy did not significantly affect visual acuity in any of them.

Conclusions: BBBD may cause maculopathy in almost two-thirds of patients treated for PCNSL, without affecting significantly the visual acuity. Intravitreal injection of MTX, according to the protocol which we apply, is not associated with maculopathy.

Footnotes

  • Competing interests: None.

  • Patient consent: Each patient gave their informed consent for the treatment.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.